Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

Recruiting

Phase 3

Bimatoprost & TimololEvaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

Sponsor:

SpyGlass Pharma, Inc.

Code:

NCT07218783

Conditions

Cataract

Glaucoma

Ocular Hypertension

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

Bimatoprost Implant System

SpyGlass IOL

Timolol Maleate Ophthalmic Solution, 0.5%

Commercial IOL

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-28. This information was provided to ClinicalTrials.gov by SpyGlass Pharma, Inc. on 2025-10-20.